Return to content in this issue

 

B cells and COVID-19: Lessons from agammaglobulinemia patients and the study of functional B cell polymorphisms

Speletas M1, Raftopoulou S1, Farmaki E2, Gatselis N3, Germanidis G4, Mouchtouri V5, Hatzianastasiou S6, Georgiadou S3, Tsinti G1, Tsachouridou O4, Tseroni M6, Metallidis S4, Dalekos G3, Eibel H7, Hadjichristodoulou C5

1Department of Immunology & Histocompatibility, Faculty of Medicine, University of Thessaly, Larissa, Greece
2First Department of Pediatrics, Ippokrateion Hospital, Medical School, Aristotle University of Thessaloniki, Greece
3Department of Medicine and Research Laboratory of Internal Medicine, National Expertise Centre of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, Greece
4First Internal Medicine Department, Infectious Diseases Division, AHEPA Hospital, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
5Laboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, Larissa, Greece
6National Public Health Organization, Athens, Greece
7Center for Chronic Immunodeficiency, University of Freiburg, Freiburg, Germany

J Investig Allergol Clin Immunol 2022; Vol. 32(1)
doi: 10.18176/jiaci.0726

Key words: B cells, BTK, X-linked agammaglobulinemia, BAFFR, COVID-19